Skip to content
Home/Companies/Biotech/Zafrens

Zafrens

Biotech·US·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Zafrens?

Zafrens is currently owned by BlueYard Capital through BlueYard Capital Fund III (2022 vintage), since 2023.

Hand-verified · updated 2026-08-31

BlueYard Capital
Investor
BlueYard Capital
BlueYard Capital Fund III · 2022 · VC

Key facts

HQUS
SectorBiotech
StatusActive

More from BlueYard Capital Fund III

Other portfolio companies in the same fund.

Aerska
Aerska
Active
BiotechIreland· 2025
Corintis
Active
Deep TechSwitzerland· 2025
Grouphug
Active
AI/MLGermany· 2025
Manex AI
Manex AI
Active
AI/MLGermany· 2025
Miren
Miren
Active
Cloud InfrastructureUS· 2025
ZeroPhase
ZeroPhase
Active
Aerospace & DefenceGermany· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Zafrens

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Zafrens?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Zafrens.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue